MesenFlow Technologies SARL

MesenFlow Technologies will provide the world’s first high-throughput inflammatory human tissue engineering system for use in preclinical drug and cosmetic preclinical development. Our mission is to evaluate compound safety, efficacy & mechanism in early drug discovery, leading to reduced attrition in the clinical phase. This has been achieved by developing cutting-edge techniques in translational medicine, where the use of human tissue generates a more accurate prediction (or translation) on how drugs will behave in humans.
Our aim is to provide a commercial “fee-per-service” platform that can be used by Pharma and cosmetics companies to test their products on real human cells in blood and tissue models, before proceeding to animal and clinical testing. The technology is fully humanised, and will contribute substantially to reduced animal experimentation.
The MesenFlow Technologies platform consists of a series of in vitro technologies that allow the construction of human blood vessel under flow, with corresponding tissue models, by using freshly isolated blood and human disease clinical samples. This has led to the development of higher-throughput human "organoid" models, suitable for commercial screening and use.